Britain and America have established a important trade agreement that will preserve zero duties on British pharmaceutical shipments entering the American market.
The Terms of the Deal
Under the terms of the agreement, the UK has agreed to increase expenditure on pharmaceuticals through the NHS. This pledge ensures that duties on these vital goods will be held at zero for a period of 36 months.
This development comes after recent warnings to hike tariffs on patented pharmaceutical products, with figures floated up to 100%.
"This deal with the United Kingdom bolsters the global environment for cutting-edge drugs and establishes much-needed equity to transatlantic medicine commerce," an announcement noted.
Trade Importance
Medicines represent one of the UK's most significant goods shipped to the US, which is clearly the biggest destination for major companies like GSK and AstraZeneca.
Export figures reveal that in the 12 months prior to last September, the UK exported medicines valued at billions to the US. This figure made up a significant portion of total UK exports in that timeframe.
"This deal secures employment, stimulates capital expenditure and paves the way for the UK to become a global hub for medical research," a minister commented.
Key NHS Changes
The agreement entails several notable changes from the UK:
- Price Threshold Increase: The UK will lift the price threshold at which it judges new therapies to be prohibitively costly by 25%.
- Higher Drug Budget: There is a aim to increase overall health service expenditure on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
- Payback Limit: The amount drug companies must refund to the NHS to prevent overspending will be restricted at fifteen percent. Last year, refunds topped 20%.
Industry Background
The pact follows a protracted tension between the pharmaceutical industry and the ministers over spending levels and NHS adoption.
These tensions were exacerbated by claims that American customers were paying a premium for the identical medicines than people in the Britain and the EU.
In recent months, several significant drug company projects in the UK have been delayed or abandoned, while multi-billion-dollar expansions have been directed toward American operations.
The Science Minister acknowledged that the NHS had to increase expenditure on treatments, noting that its expenditure on drugs had declined as a proportion of its overall budget over the previous ten-year period.
